POLBF - Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies
(NewsDirect)
Poolbeg Pharma Plc chief business officerDavid Allmond joined Proactive's Stephen Gunnion with details ofindependent research that confirms the massive market potential forPoolbeg's POLP 001 in cancer immunotherapies.
This asset is being explored for itsability to potentially prevent or treat cytokine release syndrome(CRS), a significant side effect of cancer immunotherapies. With thecancer immunotherapy market expected to reach $140 billion by 2030,POLB 001 presents an over $10 billion opportunity if successful.
Additionally, Allmond elaborated onPoolbeg's increasing emphasis on rare and orphan diseases,leveraging its ongoing programs in influenza with POLB 001, obesity,metabolic conditions, and AI-driven discovery for novel targets. Thecompany is actively considering strategies to acquire near-stagecommercial or in-market products in this high unmet need, limitedcompetition sector.
This approachaligns with Poolbeg's evolution towards a commercial-stageorganization, aiming to generate revenue and continue its growthtrajectory. Furthermore, Allmond explained how POLB 001 fits into therare orphan disease space, given its potential applications in orphancancers where immunotherapies have shown success.
Poolbeg'sstrategic pivot towards rare and orphan diseases complements itsexisting portfolio, aiming for a dual-track growth strategy focusingon both its current programs and commercial opportunities in the rareand orphan disease market.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.